Royalty Pharma (RPRX) Invested Capital (2019 - 2026)

Royalty Pharma has reported Invested Capital for 8 years, with the latest figure at $380.0 million in Q1 2026.

• Quarterly Invested Capital fell 61.95% year-over-year to $380.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 28.53% YoY) and the FY2025 annual result came in at $380.0 million, down 61.92% from the prior year.
• Invested Capital was little changed at $380.0 million in Q1 2026 per RPRX's latest filing, from $380.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $999.4 million in Q2 2025 and troughed at $116.0 million in Q2 2022.
• A 5-year average of $719.7 million and a median of $996.9 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2026: Invested Capital surged 824.19% in 2022, then sank 61.95% in 2026.
• Over 5 years, Invested Capital stood at $997.5 million in 2022, then advanced by 0.19% to $999.4 million in 2023, then fell by 0.16% to $997.8 million in 2024, then sank by 61.92% to $380.0 million in 2025, then changed by 0.0% to $380.0 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $380.0 million, $380.0 million, and $380.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.